IPO round-up: TriVascular tries for $100m; Lombard's stateside plans progress
This article was originally published in Clinica
After a flurry of recent medtech IPO filings, endovascular graft firm TriVascular Technologies is the latest to try its luck on the public market. The firm is hoping to raise up to $100m, but didn’t say how many shares it plans to sell or at what price. If successful, it will trade on Nasdaq under the ticker symbol TRIV.